El interés en corto de CrowdStrike Holdings da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de CrowdStrike Holdings. Los datos de interés en corto se actualizan cada dos semanas.

CrowdStrike Holdings (NASDAQ:CRWD) Bolsa, Informe de interés en corto

CROWDSTRIKE HOLDINGS INC - A

CrowdStrike Holdings

CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.

CrowdStrikeKirkland,,Washington, - ,Usa,-,December,10,2019:,"crowdstrike",Sign

News

Movers

CRWD

CrowdStrike decepciona en ingresos y previsiones, pese a buenos beneficios y fuerte impulso en ciberseguridad basada en IA.

CrowdStrike cae tras resultados mixtos y previsiones por debajo del consenso

Dollar Tree

Earnings

Equities

DLTR

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: DLTR, CRWD, THO, HPE y PVH.

5 acciones en el foco este miércoles: DLTR, CRWD, THO, HPE y PVH

Screenshot,Of,Buying,Male,Stocks,And,Futures,Markets,In,Thailand

Markets

$BTC

CRWV

HOOD

NVDA

Los mercados bursátiles de Estados Unidos cerraron en terreno positivo ayer, con el índice Nasdaq ganando más de 150 puntos, un alza del 0,8 %, hasta los 19.398,86 puntos. El S&amp;P 500 avanzó un 0,58 % y terminó en 5.970,37, mientras que el Dow Jones sumó un 0,5 %, cerrando en 42.519,64.

CoreWeave, Nvidia, Wells Fargo, CrowdStrike, Robinhood: 5 valores que están en el radar de los inversores

CrowdStrike Holdings, Inc. - Class A Common Stock

CrowdStrike Holdings Inc

<a href="https://www.chicagofed.org/publications/speeches/2025/june-23-milwaukee-business-journal">https://www.chicagofed.org/publications/speeches/2025/june-23-milwaukee-business-journal</a>

Politics

Economics

General

Fed's Goolsbee Says Broad Agreement Central Bank Independence Is Critical; Says Won't Get In Partisan Battles Over Fed Policy; Says Is Neutral On Crypto, Mostly Focused On Financial Stability

Highest Performances Holdings Inc. - American Depository Shares

MAAS

Trading Halt: Halt status updated at 1:55:00 PM ET: Quotation Resumption: News and Resumption Times

Morgan Stanley analyst Betsy Graseck maintains Goldman Sachs Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) with a Equal-Weight and raises the price target from $570 to $592.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Goldman Sachs Group, Raises Price Target to $592

Impact Biomedical, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock is trading sharply higher Monday after the company announced a limited merger and share exchange agreement <a href="https://www.benzinga.com/pressreleases/25/06/g46049036/dr-ashleys-limited-and-impact-biomedical-inc-announce-strategic-merger">with Dr. Ashleys</a>.
What To Know: Biopharmaceuticals developer Impact Biomedical and Dr. Ashleys entered into a strategic merger agreement under which Dr. Ashleys will acquire Impact Biomedical in a reverse merger. The combined company will be listed on the NYSE American under the name &#8220;Dr Ashleys Limited.&#8221;
The transaction is expected to create a new entity, with both Impact Biomedical and Dr. Ashleys becoming wholly owned subsidiaries of the new parent company. Dr. Ashleys will lead the combined company's operations and board of directors.
The deal is expected to help accelerate development and market reach for Impact Biomedical's pharmaceutical patents.
"We are thrilled to join forces with Dr. Ashleys Limited," said Frank Heuszel, CEO of Impact Biomedical. "Their global reach and financial strength will provide the resources and infrastructure needed to bring our innovations to market."
Impact Biomedical is a micro-cap stock with a total market capitalization of $4.38 million as of Friday&#8217;s close. Micro-cap stocks tend to be extremely volatile. 
Related Link: <a href="https://www.benzinga.com/news/entertainment/25/06/46057166/disneys-elio-posts-worst-pixar-opening-heres-why-media-giant-likely-isnt-worried">Disney&#8217;s &#8216;Elio&#8217; Posts Worst Pixar Opening: Here&#8217;s Why Media Giant Likely Isn&#8217;t Worried</a>
IBO Price Action: At the time of writing, Impact BioMedical stock was up 373.6% at $1.71, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjTu6rE_IeOAxUvlYkEHfk5LXkQFnoECDEQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image via Shutterstock.

Impact BioMedical Stock Is Soaring Monday: What's Going On?

<a href="https://techcrunch.com/2025/06/23/over-a-million-people-now-have-access-to-the-gen-ai-powered-alexa/">https://techcrunch.com/2025/06/23/over-a-million-people-now-have-access-to-the-gen-ai-powered-alexa/</a>

AMZN

'Over A Million People Now Have Access To The Gen-Ai Powered Alexa+'- Techcrunch

Morgan Stanley analyst Betsy Graseck maintains Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) with a Overweight and raises the price target from $90 to $94.

Morgan Stanley Maintains Overweight on Citigroup, Raises Price Target to $94

Morgan Stanley analyst Betsy Graseck maintains Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) with a Overweight and raises the price target from $47 to $49.

Morgan Stanley Maintains Overweight on Bank of America, Raises Price Target to $49

Guggenheim analyst Jonathan Lee maintained a <a target="_blank" href="https://www.benzinga.com/quote/ACN/analyst-ratings" rel="noreferrer noopener">Buy rating</a> on Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a lowered price forecast of $335 from&nbsp;$360 on Monday.
Accenture <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/06/46024923/accenture-new-bookings-fall-in-q3-but-it-raises-profit-outlook" rel="noreferrer noopener">reported third-quarter</a> earnings of $3.49 per share, topping&nbsp;the&nbsp;analyst consensus estimate of $3.31.
The company reported sales of $17.7 billion, slightly exceeding the analyst consensus estimate of $17.30 billion. Sales increased 8% in U.S. dollars and 7% in local currency.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/05/45538647/accenture-dell-nvidia-deliver-on-premise-ai-solution-for-regulated-industries" rel="noreferrer noopener">Accenture, Dell, NVIDIA Deliver On-Premise AI Solution For Regulated Industries</a>
Accenture narrowed its fiscal year 2025 revenue growth outlook to 6%-7% (prior 5%-7%) in local currency. The company forecasts 2025 diluted earnings of $12.77-$12.89 (prior $12.55-$12.79) per share, compared&nbsp;to the consensus of $12.75.
Ongoing business momentum allowed management to raise its fiscal 2025 revenue growth outlook, though operating margin expansion expectations ticked lower, in line with Lee&#8217;s preview.
Management highlighted a &#8220;strong pipeline&#8221; driven by enterprises looking to &#8220;leapfrog&#8221; technology investments. They also noted improvements in the pricing environment, a significant positive shift from prior quarters.
The analyst said that raising Accenture&#8217;s fiscal 2025 revenue growth outlook does little to ease investor concerns about potential softness in fiscal 2026.
The analyst expects investors to remain skeptical of Accenture&#8217;s fiscal 2026 growth despite these factors. This skepticism stems from several concerns: new bookings of $19.7 billion were down 6.5% constant currency, headcount saw a 130 basis point sequential decline, and early signs of DOGE-related headwinds are expected to impact revenue. Specifically, these headwinds are projected to be a 2% headwind on fiscal fourth-quarter revenue growth.
Accenture&#8217;s consolidated growth for fiscal 2026 will likely be impacted by a prudent decision to make fewer acquisitions this year. According to Lee, this is because potential targets aren&#8217;t meeting their economic hurdles, a &#8220;market condition&#8221; dynamic. Management is now targeting an approximately 2% inorganic contribution for future years.
The analyst said that to meet the clients&#8217; needs better, management announced a reorganization to streamline its go-to-market (GTM) structure and reduce silos across the organization, consolidating businesses under its Reinvention Services business unit.
While Lee acknowledges that Accenture will likely benefit from long-term tailwinds like widespread technological adoption and cost-cutting initiatives, he believes investor fears about estimate risk, whether cyclical or structural, are unlikely to abate in the near term.
Lee adjusted his fiscal 2025 estimates for Accenture, raising revenue to $69.38 billion (from $68.95 billion) and adjusted EPS to $12.85 (from $12.71). For fiscal 2026, he also increased revenue to $72.84 billion (from $72.37 billion) and adjusted EPS to $13.93 (from $13.91).
Price Action:&nbsp;ACN stock was trading higher by 1.28% to $289.03 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46057051/why-googles-ai-shift-could-redefine-search-and-make-clicks-less-relevant" target="_blank" rel="noreferrer noopener">Why Google&#8217;s AI Shift Could Redefine Search, And Make Clicks Less Relevant</a></li>
</ul>
Photo via Shutterstock

Reiteration

Tech

Trading Ideas

Accenture's Raised Outlook Fails To Ease Fiscal 2026 Softness Worries: Analyst

CorMedix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares are hitting new 52-week highs on Monday after the company raised its sales guidance <a href="https://www.benzinga.com/pressreleases/25/06/g46048778/cormedix-inc-announces-customer-implementation">for the second quarter</a>.
What Happened: CorMedix said one of its Large Dialysis Organization (LDO) customers has started ordering with planned implementation in the second half of 2025.
The company said that implementation of its DefenCath catheter lock solution will initially target at least 50% more patients than previously planned with opportunity for even further expansion.
As a result, CorMedix made adjustments to its agreement with the customer and now expects a modest revenue increase in June with continued growth anticipated in the second half of the year. The company updated its second-quarter net sales guidance from $31 million to a range of $35 million to $40 million to reflect the expected increased use of product by the customer.
&#8220;Their implementation of our product will provide access to DefenCath for thousands of adult patients at risk for catheter related bloodstream infections,&#8221; said Joseph Todisco, CEO of CorMedix.
D. Boral Capital analyst Jason Kolbert maintained CorMedix with a Buy rating on Monday and reiterated a price target of&nbsp;$15.
<h3 class="wp-block-heading">How To Buy CRMD Stock</h3>
By now you're likely curious about how to participate in the market for Cormedix &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
CRMD Price Action: <a href="http://benzinga.com/quote/CRMD">CorMedix shares</a> were up 23% at $16.74 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. CorMedix has traded as low as $3.61 over the past year. The stock is up approximately 111% on a year-to-date basis.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/upgrades/25/06/46051518/this-ventas-analyst-turns-bullish-here-are-top-5-upgrades-for-monday">This Ventas Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46050799/hims-hers-health-stock-is-tumbling-monday-whats-happening">Hims &amp; Hers Health Stock Is Tumbling Monday: What&#8217;s Happening?</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/MacroEcon">MacroEcon</a>/Shutterstock.

CRMD

CorMedix Stock Hits New 52-Week High On Updated Guidance: The Details

Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) reported better-than-expected first-quarter adjusted EPS <a href="https://www.benzinga.com/quote/KR/earnings">results on Friday</a>.
The company reported first-quarter adjusted earnings per share of $1.49, beating the analyst consensus estimate of $1.46. Quarterly sales of $45.12 billion missed the Street view of $45.19 billion, with identical sales ex-fuel increasing 3.2%.
Gross margin in the quarter under review increased to 23% from 22% a year ago. The improvement in gross margin was primarily attributable to the sale of Kroger Specialty Pharmacy, lower shrink, and lower supply chain costs, partially offset by the mix effect from growth in pharmacy sales which have lower margins.
"Our strong sales results and positive momentum give us confidence to raise our identical sales ex-fuel guidance, to a new range of 2.25% to 3.25%. While first-quarter sales and profitability exceeded our expectations, the macroeconomic environment remains uncertain, and as a result, other elements of our guidance remain unchanged," CFO David Kennerley said.
Kroger shares gained 2.4% to trade at $73.72 on Monday.
These analysts made changes to their price targets on Kroger following earnings announcement.
<ul class="wp-block-list">
<li>Deutsche Bank analyst Paul Trussell maintained Kroger with a Hold and raised the price target from $57 to $67.</li>
<li>Telsey Advisory Group analyst Joseph Feldman maintained the stock with an Outperform rating and raised the price target from $73 to $82.</li>
<li>UBS analyst Michael Lasser maintained the stock with a Neutral and raised the price target from $66 to $74.</li>
<li>Guggenheim analyst John Heinbockel maintained Kroger with a Buy and boosted the price target from $73 to $78.</li>
<li>Morgan Stanley analyst Simeon Gutman maintained the stock with an Equal-Weight rating and raised the price target from $71 to $76.</li>
</ul>
Considering buying KR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/KR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23123159/image-341-1024x579.png" alt="" class="wp-image-958455" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23123159/image-341-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23123159/image-341-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23123159/image-341-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23123159/image-341.png 1100w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

These Analysts Raise Their Forecasts On Kroger After Stronger-Than-Expected Q1 Earnings

Macro Notification

Reuters Cites Senior Regional Source Saying Iran Informed U.S. Via Two Diplomatic Channels Hours Ahead Of Attacks On Qatar, Tehran Also Informed Doha

Goldman Sachs analyst Leah Jordan initiates coverage on Tyson Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) with a Buy rating and announces Price Target of $67.

Initiation

Goldman Sachs Initiates Coverage On Tyson Foods with Buy Rating, Announces Price Target of $67

COMPASS Pathways Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met <a href="https://www.benzinga.com/news/health-care/25/06/46056104/why-is-compass-pathways-stock-trading-lower-on-monday">lofty investor expectations</a>.
What To Know: The study evaluated COMP360, a single-dose treatment consisting of a synthetic, proprietary formulation of psilocybin, for people with treatment-resistant depression.
A single dose of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity compared to placebo based on the Montgomery-Åsberg Depression Rating Scale (MADRS).
The primary goal was to measure changes in depression severity six weeks after treatment. Compass said the ongoing Phase 3 trial met its primary endpoint. The company reported a clinically meaningful difference of -3.6 in change at the primary endpoint, which may be impacting the stock Monday afternoon.
An independent safety board reviewed the data and reported no unexpected safety issues or meaningful differences in suicidal ideation between groups. The company also plans to discuss the preliminary results with the U.S. Food and Drug Administration (FDA), which has not yet reviewed the data.
The company said a second Phase 3 trial remains underway, with 26-week results expected in the second half of 2026.
&#8220;We eagerly anticipate further insights once we have the full dataset, and also look forward to findings from COMP006, which will explore the efficacy of two fixed doses,&#8221; said Kabir Nath, CEO of Compass Pathways.
Evercore ISI Group analyst Josh Schimmer downgraded Compass Pathways from Outperform to In-Line and lowered the price target from $11 to $6, which appears to be adding to the sell-off on Monday. 
CMPS Price Action: At the time of publication, Compass shares were down 46.2% at $2.49, according to data from <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46056665/unitedhealth-cvs-among-major-insurers-to-fast-track-prior-authorizations-will-it-cut-profits-even-more">UnitedHealth, CVS Among Major Insurers To Fast-Track Prior Authorizations: Will It Cut Profits Even More?</a></li>
</ul>
Image: Vinnikava Viktoryia/Shutterstock.

CMPS

Compass Pathways Stock Is Plunging Today: What's Going On?

Fed's Goolsbee Says So Far Immigration Enforcement Hasn't Had Major Job Market Impact

In the battle of Silicon Valley titans, Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is leaving Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) in the dust &#8211; on both the income statement and <a href="https://www.benzinga.com/quote/nvda/news">the stock chart</a>. 
Despite generating almost four times as much revenue as Intel on an annualized basis, as Beth Kindig, the lead tech analyst at I/O Fund, noted on X, Nvidia trades at less than half Intel's forward price-to-earnings ratio. If that sounds backwards, you're not alone.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Nvidia <a href="https://twitter.com/search?q=%24NVDA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$NVDA</a> now earns almost as much revenue per quarter as Intel <a href="https://twitter.com/search?q=%24INTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$INTC</a> does in one year.
&mdash; Beth Kindig (@Beth_Kindig) <a href="https://twitter.com/Beth_Kindig/status/1935411163673543020?ref_src=twsrc%5Etfw">June 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
For its last reported quarter, Nvidia grossed $44 billion in revenues. This, compared to Intel&#8217;s last reported quarterly revenue of $12.67 billion, shows the former&#8217;s dominant positioning. For the year ended December 2024, Intel grossed $53 billion in annual revenues. 
Moreover, Nvidia has ben growing its quarterly revenue at a rate of <a href="https://seekingalpha.com/symbol/NVDA/income-statement">70%</a> YoY for the past two reported quarters. Won&#8217;t be long before Intel&#8217;s annual revenue has a tough time catching up with Nvidia&#8217;s quarterly revenue.
Despite the huge gap in revenue, the market values Nvidia's earnings far more conservatively: a forward PE of 34 versus Intel's frothy 79, per <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0620">Benzinga Pro</a> data. It's a head-scratcher &#8211; until you zoom out.
Read Also: <a href="https://www.benzinga.com/news/education/25/06/45983347/jensen-huang-gave-12-6-million-to-charity-then-nvidias-stock-made-it-billions">Jensen Huang Gave $12.6 Million To Charity, Then Nvidia&#8217;s Stock Made It Billions</a>
<h2 class="wp-block-heading">Nvidia's Growth Engine Dwarfs Intel's</h2>
Over the past decade, Nvidia has clocked a staggering <a href="https://www.alphaspread.com/security/nasdaq/nvda/financials/income-statement/revenue#:~:text=The%20average%20annual%20Revenue%20growth,over%20the%20past%20ten%20years%20.">41%</a> compound annual revenue growth, accelerating into the AI era with unmatched momentum. That's not just fast &#8211; it's Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)-fast, even outpacing Elon Musk's empire, which posted a <a href="https://www.alphaspread.com/security/nasdaq/tsla/financials/income-statement/revenue#:~:text=The%20average%20annual%20Revenue%20growth,over%20the%20past%20ten%20years%20.">39%</a> CAGR over the same period.
And the stock? Nvidia's total return of 26,420% over the last 10 years &#8211; translating to a 75% CAGR &#8211; makes even Tesla's 1,740% return (34.6% CAGR) look tame. Meanwhile, Intel&#8217;s revenue has displayed <a href="https://www.alphaspread.com/security/nasdaq/intc/financials/income-statement/revenue#:~:text=The%20average%20annual%20Revenue%20growth,over%20the%20past%20ten%20years%20.">negative</a> compounded growth rates over the past three, five and 10 year periods.
This isn't just hype. It's a decade of dominant execution, powered by GPU leadership in gaming, AI training, and data centers. With the upcoming rollout of next-gen Blackwell chips and hyperscaler demand at full tilt, Nvidia's growth story still has legs.
<h2 class="wp-block-heading">Intel's Valuation Looks Disconnected From Reality</h2>
Meanwhile, Intel's valuation seems to live in a parallel universe. Its forward PE of 79 suggests either a miraculous turnaround in earnings or blind hope. While CEO Pat Gelsinger is pushing hard on foundry ambitions and AI chips, results have yet to catch up &#8211; and the revenue gap with Nvidia continues to widen.
So while Nvidia may seem expensive in absolute terms, it's arguably the better bargain when looking at what you get for every dollar invested.
For investors, the message is clear: growth, not nostalgia, is driving the market &#8211; and Nvidia is riding that wave better than anyone.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46013679/dan-ives-says-market-is-massively-underestimating-this-ai-play-urges-investors-to-look-beyong-mag-7">Dan Ives Says Market Is &#8216;Massively Underestimating&#8217; This AI Play, Urges Investors To Look Beyong Mag 7</a></li>
</ul>
Photo: Shutterstock

Long Ideas

INTC

TSLA

Nvidia Makes 4x Intel's Revenue—But Commands Half The Forward Valuation

Evercore ISI Group analyst Josh Schimmer downgrades Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) from Outperform to In-Line and lowers the price target from $11 to $6.

Downgrades

Evercore ISI Group Downgrades Compass Pathways to In-Line, Lowers Price Target to $6

Darden Restaurants Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) reported better-than-expected fourth-quarter <a href="https://www.benzinga.com/quote/DRI/earnings">financial results on Friday</a>.
The company reported fourth-quarter adjusted earnings per share of $2.98, beating the analyst consensus estimate of $2.97. Quarterly sales of $3.27 billion outpaced the analyst consensus estimate of $3.26 billion.
Darden reported a consolidated same-restaurant sales increase of 4.6%, with Olive Garden and LongHorn Steakhouse rising 6.9% and 6.7%, respectively. Fine Dining saw a decline of 3.3%, while Other Business grew by 1.2%.
&#8220;We had a strong quarter with same-restaurant sales and earnings growth that exceeded our expectations,&#8221; said Darden President &amp; CEO Rick Cardenas. &#8220;Our adherence to our winning strategy, anchored in our four competitive advantages and being brilliant with the basics, led to a successful year. Our strategy remains the right one for the company, and we will continue to execute it to drive growth and long-term shareholder value.&#8221;
Darden Restaurants expects fiscal 2026 adjusted EPS between $10.50 and $10.70, below the $10.75 consensus estimate. The company projects total sales growth of 7% to 8% for the year.
Darden shares fell 5.1% to trade at $214.17 on Monday.
These analysts made changes to their price targets on Darden following earnings announcement.
<ul class="wp-block-list">
<li>Stephens &amp; Co. analyst Jim Salera maintained Darden Restaurants with an Equal-Weight rating and raised the price target from $200 to $212.</li>
<li>Baird analyst David Tarantino maintained Darden Restaurants with a Neutral and raised the price target from $218 to $230.</li>
<li>Keybanc analyst Eric Gonzalez maintained the stock with an Overweight rating and raised the price target from $230 to $245.</li>
<li>B of A Securities analyst Sara Senatore maintained Darden Restaurants with a Buy and raised the price target from $252 to $253.</li>
<li>TD Securities analyst Andrew Charles maintained the stock with a Hold and boosted the price target from $215 to $235.</li>
<li>Barclays analyst Jeffrey Bernstein maintained Darden Restaurants with an Overweight rating and raised the price target from $235 to $255.</li>
<li>Citigroup analyst Jon Tower maintained the stock with a Buy and raised the price target from $245 to $253.</li>
</ul>
Considering buying DRI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/DRI/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="569" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23120843/image-337-1024x569.png" alt="" class="wp-image-958401" style="width:597px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23120843/image-337-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23120843/image-337-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23120843/image-337-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23120843/image-337.png 1160w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

These Analysts Boost Their Forecasts On Darden Restaurants Following Better-Than-Expected Q4 Results

Macro Economic Events

Fed's Goolsbee Says Notes Budgets Being Squeezed At Government Statistical Agencies; Says Government Data Could Get Noisier On Budget Cutbacks; Says  It's Become Less Clear What Some Of Best Economic Indicators Mean

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are putting the pedal to the floor in Monday&#8217;s regular trading session following the company&#8217;s <a href="https://www.benzinga.com/markets/tech/25/06/46045542/tesla-launches-robotaxi-in-austin-elon-musk-calls-it-a-culmination-of-a-decade-of-hard-work">robotaxi launch in Austin, Texas</a>. 
What To Know: Tesla CEO Elon Musk announced in a <a href="https://x.com/elonmusk/status/1936876178356490546">post</a> on X that Tesla&#8217;s robotaxi launch in Austin was &#8220;successful.&#8221; The EV maker officially kicked off robotaxi rides on Sunday through an invitation-only event that involved a limited number of riders. 
&#8220;Super congratulations to the @Tesla_AI software &amp; chip design teams on a successful @Robotaxi launch!! Culmination of a decade of hard work,&#8221; Musk said in the post.
Some of the invitees included Tesla shareholders and long-time promoters of the company often seen posting on X. Riders were charged a flat fee of $4.20 per ride, Musk said in an X <a href="https://x.com/elonmusk/status/1936834688188129503">post</a>. 
Musk told CNBC's&nbsp;David Faber&nbsp;in an <a href="https://www.benzinga.com/25/05/45529030/elon-musk-confirms-tesla-robotaxi-launch-is-on-track-for-next-month-these-things-happen-slowly-but-then-all-at-once">interview</a> last month that he expected the company to have about 1,000 driverless vehicles on the roads within a few months of launch. He further estimated that Tesla could have hundreds of thousands of vehicles capable of unsupervised full self-driving on the roads by the end of next year, "if not over a million."
In a CNBC interview on Monday, Wedbush&#8217;s Dan Ives <a href="https://x.com/TheSonOfWalkley/status/1937130279618887861">predicted</a> that Tesla will quickly expand the robotaxi rollout to 25 to 30 cities within a year. He added that autonomous driving is worth $1 trillion alone for Tesla&#8217;s valuation. 
Ives was among those who attended the robotaxi launch in Austin over the weekend. In a new note to clients, he said the launch exceeded his expectations. 
&#8220;Going into it, we expected to be impressed but walking away from it, all there is to say is that this is the future,&#8221; Ives said in the note. 
&#8220;To really put it into perspective, there was a moment where we drove up a narrow road going up a hill with cars parked on both sides with oncoming traffic and people opening their car doors into the road and the Robotaxi masterfully maneuvered with patience and safety among this chaos.&#8221;
Ives maintained an Outperform rating on Tesla shares with a 12-month price target of $500. 
Other analysts don&#8217;t appear to be as impressed with UBS maintaining a Sell, while lifting its target to $215, and Guggenheim reiterating a Sell and price target of $175. 
Guggenheim analysts believe robotaxi expectations are already embedded in the company&#8217;s &#8220;lofty&#8221; valuation. Guggenheim noted that it needs to see the rollout accelerate into the end of the year in order to justify Tesla&#8217;s stock price. 
The Direxion Daily TSLA Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLL#NASDAQ">TSLL</a>) was up about 19.5% at last check, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
TSLA Price Action: <a href="http://benzinga.com/quote/TSLA">Tesla shares</a> were up 9.83% at $354.22 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46046720/tesla-doubles-down-on-us-elon-musk-plans-another-8-billion-investment-after-spending-nearly-10-billion-in-2024">Tesla Doubles Down On US — Elon Musk Plans Another $8 Billion Investment After Spending Nearly $10 Billion In 2024</a></li>
</ul>
Photo: Shutterstock.

Analyst Color

TSLL

Tesla Stock Is Surging Today: What's Driving The Momentum?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$350.00</td>
<td>$117.0K</td>
<td>15.1K</td>
<td>133.9K</td>
</tr>
<tr>
<td>CMG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/25/25</td>
<td>$54.00</td>
<td>$33.3K</td>
<td>218</td>
<td>5.0K</td>
</tr>
<tr>
<td>XPEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$19.00</td>
<td>$28.3K</td>
<td>13.2K</td>
<td>277</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we notice a call option sweep that happens to be bearish, expiring in 4 day(s) on June 27, 2025. This event was a transfer of 117 contract(s) at a $350.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $117.0K, with a price of $1000.0 per contract. There were 15117 open contracts at this strike prior to today, and today 133988 contract(s) were bought and sold. 
• For CMG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), we notice a call option sweep that happens to be bullish, expiring in 32 day(s) on July 25, 2025. This event was a transfer of 147 contract(s) at a $54.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $33.3K, with a price of $227.0 per contract. There were 218 open contracts at this strike prior to today, and today 5026 contract(s) were bought and sold. 
• Regarding XPEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), we observe a put option sweep with bullish sentiment. It expires in 25 day(s) on July 18, 2025. Parties traded 251 contract(s) at a $19.00 strike. This particular put needed to be split into 41 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $113.0 per contract. There were 13277 open contracts at this strike prior to today, and today 277 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

CrowdStrike Holdings

Interés en corto

CrowdStrike Holdings (NASDAQ:CRWD) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL